Giuseppe Lo Russo - Concepedia

Author

Giuseppe Lo Russo

Fondazione IRCCS Istituto Nazionale dei Tumori ORCID

Also Known As

G Lo Russo, G Russo, G. Lo Russo, G. Russo, G.L.o. Russo, Giuseppe Lo Russo, Giuseppe Lo Russo, Giuseppe Russo, Spinelli, Gian Paolo, Teresa Beninato

330

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori Istituti di Ricovero e Cura a Carattere Scientifico University of Milan Mario Negri Institute for Pharmacological Research Azienda Ospedaliero-Universitaria Careggi

About

Giuseppe Lo Russo is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	1.2K
2	Health Sciences	5	5	134
3	Engineering	1	1	31
4	Public Health	1	1	84
5	Cell Biology	1	1	32

Giuseppe Lo Russo

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, Clinical Cancer Research	2018	400
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors Giovanni Fucà, Giulia Galli, M. Poggi, ESMO Open	2019	203
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors Andrew J. Wagner, Udai Banerji, Amit Mahipal, Journal of Clinical Oncology	2017	125
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues Sara Pusceddu, Claudio Vernieri, Massimo Di Maïo, Gastroenterology OncologyPancreatic CancerMedicineDiabetesLonger Progression-free Survival	2018	87
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial Quincy S. Chu, Laurent Greillier, Wei Tu, The Lancet Chemotherapy Versus ChemotherapyOncologyPathologyPleural DiseaseCancer Treatment	2023	86
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients Marina Chiara Garassino, Alain Gelibter, Francesco Grossi, Journal of Thoracic Oncology Preclinical TherapeuticsTobacco ControlCancer ScreeningMedicineCancer Management	2018	84
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study Mattia Boeri, Massimo Milione, Claudia Proto, Clinical Cancer Research	2019	81
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort Arsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, Cancers ImmunologyImmunotherapeuticsImmunotherapyOncologyDeath Ligand 1	2019	77
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? Jacob J. Adashek, Shumei Kato, Roberto Ferrara, The Oncologist Mdm2 AmplificationCancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsImmunology	2019	74
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer Giulia Galli, Tiziana Triulzi, Claudia Proto, Lung Cancer AntibioticsMedicineImmunologyAntimicrobial ResistanceAntimicrobial Chemotherapy	2019	73

Page 1